Arkolith/Insider Trading/RARE/Form 4

Horn Howard

Chief Financial OfficerUltragenyx Pharmaceutical Inc. (RARE) · full profile →Form 4 · filed Mar 3, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$228K
Net Open-Market Flow
-$228K
Transactions
4
4 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 3, 2026Sell(S)2K$22.40$37K85K
Mar 2, 2026Sell(S)5K$22.80$121K90K
Mar 2, 2026Sell(S)3K$22.54$70K87K
Mar 1, 2026Grant(A)6K—$095K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-089107) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML